CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $28.50 Average Price Target from Analysts
CytomX Therapeutics, Inc. (NASDAQ:CTMX) has received a consensus rating of “Hold” from the ten analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $28.50.
Several brokerages have commented on CTMX. BidaskClub cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price target on shares of CytomX Therapeutics in a research report on Wednesday, April 26th. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 29th. HC Wainwright reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Monday, May 8th. Finally, ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th.
In other news, insider Sean A. Mccarthy sold 4,481 shares of the company’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $15.00, for a total value of $67,215.00. Following the sale, the insider now directly owns 8,726 shares of the company’s stock, valued at approximately $130,890. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sean A. Mccarthy sold 4,781 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $15.52, for a total transaction of $74,201.12. Following the completion of the sale, the insider now directly owns 9,026 shares in the company, valued at $140,083.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,062 shares of company stock worth $497,641. 8.00% of the stock is owned by insiders.
Large investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the first quarter worth about $313,000. Vident Investment Advisory LLC boosted its stake in shares of CytomX Therapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 75,924 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 12,652 shares during the last quarter. Hamilton Lane Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the first quarter worth about $366,000. Russell Investments Group Ltd. purchased a new stake in shares of CytomX Therapeutics during the fourth quarter worth about $243,000. Finally, Spark Investment Management LLC boosted its stake in shares of CytomX Therapeutics by 52.5% in the first quarter. Spark Investment Management LLC now owns 101,700 shares of the biotechnology company’s stock worth $1,756,000 after buying an additional 35,000 shares during the last quarter. 52.33% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $28.50 Average Price Target from Analysts” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/08/cytomx-therapeutics-inc-nasdaqctmx-receives-28-50-average-price-target-from-analysts.html.
CytomX Therapeutics (NASDAQ CTMX) traded up 5.27% during trading on Friday, reaching $14.37. The company’s stock had a trading volume of 130,273 shares. CytomX Therapeutics has a 52 week low of $9.84 and a 52 week high of $20.02. The company’s market cap is $528.08 million. The company’s 50 day moving average price is $14.72 and its 200 day moving average price is $14.43.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. On average, equities analysts anticipate that CytomX Therapeutics will post ($1.41) earnings per share for the current fiscal year.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.